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Abstract
Background—Although cholesterol levels are known to be decreased in sickle cell disease 
(SCD), the level of pro-inflammatory high density lipoprotein cholesterol (proHDL) and its 
association with clinical complications and laboratory variables has not been evaluated.
Design and Methods—Plasma levels of total cholesterol, high density lipoprotein cholesterol 
(HDL), proHDL and selected clinical and laboratory variables were ascertained in a cohort of 
SCD patients and healthy African American control subjects in this single center, cross-sectional 
study.
Results—Although total cholesterol was significantly lower in SCD patients compared with 
control subjects, HDL and proHDL levels were similar in both SCD and control groups. In 
univariate analyses, proHDL was correlated with echocardiography-derived tricuspid regurgitant 
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jet velocity. ProHDL was higher in SCD patients with suspected pulmonary hypertension (PHT) 
compared to patients without suspected PHT. ProHDL was positively correlated with lactate 
dehydrogenase, total bilirubin, direct bilirubin, indirect bilirubin, prothrombin fragment 1+2, D-
dimer and thrombin-antithrombin complexes (TAT). In multivariable analyses, only higher lactate 
dehydrogenase and direct bilirubin levels were associated with higher levels of proHDL.
Conclusions—SCD is characterized by hypocholesterolemia. Although proHDL is not 
increased in SCD patients compared with healthy controls, it is significantly associated with 
markers of liver disease. In addition, proHDL is associated with tricuspid regurgitant jet velocity 
and markers of coagulation, although these associations are not significant in multivariable 
analyses.
Keywords
Sickle cell disease; Pro-inflammatory HDL; Cholesterol; Coagulation activation; Pulmonary 
vasculopathy
Introduction
Sickle cell disease (SCD) is an inherited disorder characterized by the presence of chronic 
hemolysis, ischemia-reperfusion injury and organ damage. Although somewhat 
controversial, it has been proposed that the clinical manifestations of SCD may fall into two 
partially overlapping phenotypes that are characterized by the presence of chronic hemolytic 
anemia and vaso-occlusive complications (1). While the risk of atherosclerosis is thought to 
be low in SCD (2) sickle cell anemia and other related hemoglobinopathies are complicated 
by the presence of vasculopathic complications, including stroke and pulmonary 
hypertension (PHT), which may occur, at least in part, as a result of increased hemolysis (1). 
Although cholesterol levels are reported to be low in patients with various anemias (3-9), the 
association of plasma lipid subsets with clinical complications and laboratory variables in 
SCD has not been extensively evaluated.
In this study, we compared levels of plasma lipids, including total cholesterol and high-
density lipoprotein cholesterol (HDL) in SCD patients and healthy, African-American 
control subjects. As SCD is described as a chronic inflammatory state (10,11), we also 
determined the levels of pro-inflammatory HDL-cholesterol (proHDL) in this patient cohort. 
ProHDL is unable to perform the usual protective functions of HDL in the prevention of 
atherosclerosis, including the inhibition of LDL oxidation. Finally, we evaluated the 
association of selected lipid subsets (total cholesterol, HDL cholesterol and proHDL) with 
clinical complications and laboratory measures of hemolysis, activation of the coagulation 
system, inflammation, and N-terminal pro-brain natriuretic peptide (NT-proBNP) as a 
measure of elevated cardiac filling pressures.
Design and Methods
Patients and Study Design
The study patients represent a cohort followed at the Sickle Cell Clinic at the University of 
North Carolina (UNC), Chapel Hill. The data were collected as part of a study to investigate 
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the pathophysiology of PHT in SCD (12). Consecutive SCD patients seen in the clinic for 
routine follow up, who agreed to participate, were evaluated. Patients with SCD were 
assessed while in the non-crisis, “steady state;” had not experienced an episode of acute 
chest syndrome in the 4 weeks preceding enrollment; and had no clinical evidence of 
congestive heart failure. The control subjects were of African descent, had no known 
medical conditions, were not taking any medications, and were recruited by advertisement. 
Only control subjects who were not overweight or obese (i.e. had a body mass index [BMI] 
< 25) were enrolled. The study was approved by the Institutional Review Board at UNC, 
Chapel Hill and all subjects gave written informed consent to participate.
Study Measurements
Measurement of Lipid Profiles and other Laboratory Variables
Total cholesterol was quantified using a cholesterol oxidase/esterase kit from Wako 
Chemical, Inc. (Richmond, VA). HDL was isolated from whole plasma with a solution of 
dextran-sulfate-MgCl2 (10 g/l, 0.5 M) (Berkeley HeartLab Inc., Alameda, CA), which 
precipitates apoB-containing lipoproteins. HDL was quantified using an HDL cholesterol E 
kit (Wako Diagnostics, Richmond, VA). ProHDL was determined using a modified method 
of a previously published cell-free assay (13). Briefly, HDL was incubated with CuCl2 (5 
μmol/l, final concentration) for 1 hour at 37°C in a 384-well microtiter plate (MJ Research 
Inc., Waltham, MA). After incubation, 10 μl of 2′,7′-dichlorodihdrofluorescein (H2DCF) 
solution (0.2 mg/ml) was added to the HDL-Cu2+ mixture in a total volume of 50 μL. Rates 
of fluorescence (Excitation at 485 nm; Emission at 530 nm) were determined over the next 2 
hours at 30 minute intervals using a Spectra Max Gemini EM fluorescence plate reader 
(Molecular Devices, Sunnyvale, CA). The results for proHDL are presented as slopes of the 
increase in dichlorofluorescein fluorescence over time.
Commercially available enzyme-linked immunosorbent assay kits were used to measure 
human soluble vascular cell adhesion molecule-1 (sVCAM-1), D-dimer and thrombin anti-
thrombin complexes (TAT) (R&D systems, Minneapolis, Minnesota, USA), and 
prothrombin fragment 1+2 (F1+2) (Dade Behring, Marburg, Germany). Samples were 
assayed in duplicate and as per manufacturer's instructions. Measurements of routine 
laboratory tests were obtained at the McClendon Clinical Laboratory at UNC Hospitals.
SCD-Related Clinical Complications
Clinical complications in SCD patients were ascertained at the time of evaluation and 
defined using accepted definitions (14-16). Tricuspid regurgitant jet velocity (TRV) was 
measured by Doppler echocardiography as previously described (17). The estimated 
pulmonary artery systolic pressure (PASP) was calculated using the modified Bernoulli 
equation, and PHT was suspected if the PASP value, adjusted for age, sex, and body mass 
index exceeded the upper limits of normal in the reference ranges (18). All the 
echocardiograms were interpreted by a cardiologist blinded to all patient data. Only 
associations of total cholesterol, HDL and proHDL with the selected clinical and laboratory 
variables were performed because the study subjects were not required to be fasting. While 
fasting is recommended to minimize the influence of postprandial hyperlipidemia, serum 
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total cholesterol and HDL can be measured in fasting or non-fasting individuals (19). We 
have also observed differences in proHDL levels between non-fasted transgenic sickle cell 
(Berk) and control mice (Pritchard KA Jr, unpublished data).
Statistical Analyses
The normality assumption was not satisfied for continuous laboratory variables based on 
Shapiro-Wilk normality tests. Continuous variables were compared using Wilcoxon rank-
sum test. Categorical variables were compared using Pearson's chi-square test for two 
groups or Kruskal-Wallis one-way analysis of variance for more than two groups. The 
association of continuous variables with lipid variables was explored using Spearman rank 
correlations. Multiple regression analyses were conducted to investigate the association of 
each lipid variable with clinical and laboratory variables. Because the lipid variables were 
skewed, the bootstrap method was used with 10,000 replications to estimate the p value and 
95% confidence interval (20). A backward selection procedure was used for variable 
selection. The deletion criterion was based on a p value greater than 0.05 and the variable 
with the largest p value was deleted first at each step. The final model included only those 
variables which were statistically significant at 0.05 level. Reported p values are for 
individual tests, unadjusted for multiple comparisons because of the exploratory nature of 
this study. All analyses were performed using SAS (version 9.2, SAS Institute, Inc. Cary, 
NC).
Results
Demographics and Laboratory Characteristics
The demographic and laboratory characteristics of all the study subjects are shown in Table 
1. One hundred and seventeen patients with SCD (HbSS: 91; HbSC: 13; HbSβ0 thalassemia: 
5; and HbSβ+ thalassemia: 8) and 11 healthy, African American, control subjects (HbAA: 
11) were evaluated. There were no significant differences in age and gender distribution 
when SCD patients were compared to control subjects. As expected, patients with SCD had 
significantly higher WBC counts, platelet counts, reticulocyte counts, hemoglobin F, lactate 
dehydrogenase, and total and indirect bilirubin compared with control subjects, while 
hemoglobin was significantly lower in SCD patients compared with control subjects.
Plasma Lipids in Sickle Cell Disease Patients and Healthy Controls
The median level of total cholesterol was significantly lower in SCD patients than in control 
subjects (102.5 mg/dL [interquartile range {IQR}: 86.5, 112.5 mg/dL] vs. 125.4 mg/dL 
[IQR: 111.0, 152.7 mg/dL], p = 0.0036). However, there were no statistically significant 
differences in the levels of HDL (42 mg/dL [IQR: 34.0, 52.9 mg/dL] vs. 49.0 mg/dL [IQR: 
44.8, 58.0 mg/dL], p = 0.075) and proHDL (3.1 fluorescence units {FU} [IQR: 2.2, 4.2 FU] 
vs. 3.4 FU [IQR: 2.0, 4.8 FU], p = 0.61) when SCD patients were compared with control 
subjects. When the four SCD genotypes were compared, there was a trend for a difference in 
the level of total cholesterol (SS: 102.2 mg/dL [IQR: 86.4, 120.0 mg/dL] vs. Sβ0: 153.4 
mg/dL [IQR: 152.1, 154.1 mg/dL] vs. Sβ+: 103.5 mg/dL [IQR: 82.5, 141.7 mg/dL] vs. SC: 
91.0 mg/dL [IQR: 86.5, 123.3 mg/dL], p = 0.055), but no differences were seen in the levels 
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of HDL (SS: 43.3 mg/dL [IQR: 34.0, 53.8 mg/dL] vs. Sβ0: 36.4 mg/dL [IQR: 31, 45.6 
mg/dL] vs. Sβ+: 36.1 mg/dL [IQR: 32, 56 mg/dL] vs. SC: 42 mg/dL [IQR: 40.0, 50.5 mg/
dL], p = 0.75) or proHDL (SS: 3.3 Fluorescence Units {FU} [IQR: 2.2, 4.3 FU] vs. Sβ0: 2.0 
FU [IQR: 1.6, 3.0 FU] vs. Sβ+: 2.6 FU [IQR: 1.6, 3.3 FU] vs. SC: 3.2 FU [IQR: 2.4, 4.0 FU], 
p = 0.60). When SCD patients were grouped based on presumed disease severity (SS/Sβ0 
thalassemia vs. SC/Sβ+ thalassemia), there were no statistically significant differences in the 
levels of total cholesterol, HDL, or proHDL (Supplementary data, Table 1S).
In patients with SCD, proHDL was correlated with HDL (r = 0.68 [95% Confidence Interval 
{CI}: 0.57, 0.77], p < 0.0001), but there was no correlation with total cholesterol (r = −0.043 
[95% CI: −0.23, 0.14], p = 0.65).
Association of Pro-Inflammatory HDL Cholesterol, Total Cholesterol and HDL Cholesterol 
with Demographic and Clinical Variables in Patients with Sickle Cell Disease
No significant correlations were observed between age and proHDL (r = 0.17, p = 0.067), 
total cholesterol (r = 0.14, p = 0.12) or HDL (r = 0.14, p = 0.12). There were also no 
significant correlations between BMI and proHDL (r = 0.001, p = 0.99) or HDL (r = − 
0.092, p = 0.33), although there was a trend towards a significant correlation between BMI 
and total cholesterol (r = 0.18, p = 0.053). Total cholesterol level was higher in female SCD 
patients than in male patients (104.1 mg/dL [IQR: 91.6, 126.8 mg/dL] vs. 93.6 mg/dL [IQR: 
83.8, 109.7 mg/dL], p = 0.016) but there were no gender differences in proHDL or HDL.
Echocardiography-derived TRV was significantly correlated with proHDL (r = 0.28, p = 
0.016), but no correlations were observed between TRV and either total cholesterol (r = 
−0.11, p = 0.35) or HDL (r = −0.031, p = 0.79). ProHDL was higher in patients with 
suspected PHT (3.6 FU [IQR: 2.7, 5.0 FU] vs. 2.9 FU [2.0, 4.0 FU], p = 0.0099) and was 
lower in patients with a history of priapism (2.7 FU [IQR: 2.0, 4.0 FU] vs. 3.7 FU [IQR: 2.7, 
4.6 FU], p = 0.035) than in patients without these complications (Table 2). Total cholesterol 
was lower in patients with suspected PHT than in those not suspected to have PHT (95.9 
mg/dL [IQR: 80.1, 109.5 mg/dL] vs. 104.9 mg/dL [IQR: 90.2, 123.9 mg/dL], p = 0.011). 
There was also a trend for lower levels of total cholesterol in patients with histories of 
priapism (86.3 mg/dL [IQR: 80.1, 108.5 mg/dL] vs. 102.8 mg/dL [IQR: 86.5, 120.3 mg/dL], 
p = 0.063) and leg ulcers (93.6 mg/dL [IQR: 83.8, 109.5 mg/dL] vs. 103.1 [IQR: 90.9, 123.8 
mg/dL], p = 0.084). HDL was lower in patients with a history of priapism than in those 
without this complication (38.0 mg/dL [IQR: 33.0, 45.7 mg/dL] vs. 48.2 mg/dL [IQR: 37.4, 
55.6 mg/dL], p = 0.015).
Correlation of Pro-Inflammatory HDL Cholesterol, Total Cholesterol and HDL Cholesterol 
with Markers of Hemolysis, Coagulation Activation, Endothelial Injury and Inflammation in 
Patients with Sickle Cell Disease
Lipid subsets were evaluated for correlations with markers of hemolysis (hemoglobin, 
reticulocyte count, lactate dehydrogenase, as well as total and indirect bilirubin), coagulation 
activation (F1+2, D-dimer and TAT), endothelial injury (sVCAM-1), inflammation (white 
blood cell count, absolute neutrophil count and absolute monocyte count) and other selected 
laboratory variables (platelet count, fetal hemoglobin, direct bilirubin and NT-proBNP) in 
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our patient cohort. ProHDL was directly correlated with lactate dehydrogenase (r = 0.31, p = 
0.0008), total bilirubin (r = 0.23, p = 0.013), direct bilirubin (r = 0.48, p < 0.0001), indirect 
bilirubin (r = 0.21, p = 0.028), F1+2 (r = 0.33, p = 0.0062), D-dimer (r = 0.27, p = 0.0053) 
and TAT (r = 0.22, p = 0.023) (Table 3; Supplementary data - Figures 1A-G). However, no 
correlations were observed between proHDL and hemoglobin, reticulocyte count, fetal 
hemoglobin, white blood cell count, or sVCAM-1. There was a modest correlation between 
total cholesterol and fetal hemoglobin (r = 0.19, p = 0.045), with inverse correlations 
between total cholesterol and lactate dehydrogenase (r = −0.20, p = 0.031), total bilirubin (r 
= −0.22, p = 0.019), indirect bilirubin (r = − 0.20, p = 0.034), and sVCAM-1 (r = −0.34, p = 
0.0002). There appeared to be a positive correlation between total cholesterol and 
hemoglobin (r = 0.16, p = 0.085), although this did not achieve statistical significance. 
Finally, HDL was correlated with platelet count (r = −0.21, p = 0.025) and direct bilirubin (r 
= 0.39, p < 0.0001).
Multivariable Analyses
Multiple regression analysis was conducted to investigate the association of total 
cholesterol, HDL and proHDL with selected clinical and laboratory variables in SCD 
patients. The initial model included clinical variables (history of stroke, avascular necrosis, 
history of leg ulcers, history of acute chest syndrome, history of smoking, suspected PHT 
and number of pain episodes in the previous year) and laboratory variables (absolute 
neutrophil count, absolute monocyte count, hemoglobin, platelet count, lactate 
dehydrogenase, total bilirubin, direct bilirubin, sVCAM-1, D-dimer, F1+2 and TAT). In the 
final model, using only significant covariates after the model selection, sVCAM-1 was 
significantly and inversely associated with total cholesterol (estimate: −0.015, p = 0.003); 
TAT was significantly associated with HDL (estimate: 0.068, p = 0.039); and direct 
bilirubin (estimate: 1.4, p = 0.047) and lactate dehydrogenase (estimate: 0.0011, p = 
0.00024) were significantly associated with proHDL (Table 4). This means that for a 
continuous variable such as direct bilirubin, we expect an increase in proHDL by 1.4 FU for 
every 1 mg/dL increase in direct bilirubin, given the same level of lactate dehydrogenase.
Discussion
Patients with SCD have previously been reported to have lower total cholesterol and LDL 
levels compared with healthy, control subjects (3-9). Although it has been suggested that 
hypocholesterolemia is not due to increased erythropoiesis, but rather is a consequence of 
anemia (3), a study of patients with chronic anemia, including those with high erythropoietic 
activity, low erythropoietic activity and healthy, control subjects reported the presence of 
hypocholesterolemia only in patients with anemia and increased erythropoietic activity (21). 
In addition, significant inverse correlations were observed between serum levels of 
cholesterol and soluble transferrin receptor, a marker of high erythropoietic activity in the 
absence of iron deficiency, suggesting that hypocholesterolemia is associated with increased 
erythropoiesis. Although our findings of decreased total cholesterol levels in SCD patients 
and their association with measures of hemolysis in univariate analysis appear to confirm 
and extend these findings, no associations were observed between total cholesterol and any 
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measures of hemolysis in multivariable analyses, suggesting that hypocholesterolemia in 
SCD is not solely due to increased hemolysis.
While multiple studies show that HDL level is a strong predictor of cardiovascular risk 
(22-24), there is evidence that in some circumstances HDL may be dysfunctional (i.e. it fails 
to prevent the formation of and/or fails to inactivate biologically active LDL-derived 
oxidized phospholipids) or pro-inflammatory (i.e. it enhances the formation of biologically 
active oxidized phospholipids) (25-30). Elevated plasma concentrations of oxidized LDL are 
associated with coronary artery disease (31), and patients with acute coronary syndromes 
have higher levels of malondialdehyde-modified LDL than patients with stable coronary 
artery disease (32). High levels of proHDL have been observed in patients with 
inflammatory diseases such as systemic lupus erythematosus and rheumatoid arthritis (33). 
Although SCD is frequently referred to as a chronic inflammatory disease (10,11), we found 
no significant difference in the level of proHDL when SCD patients were compared with 
healthy African American controls. In addition, there were no associations between proHDL 
and any of the evaluated inflammatory markers in our study patients. The observed level of 
proHDL in this study, combined with the lower cholesterol levels in SCD patients compared 
with healthy, control subjects may contribute to the low incidence of atherosclerosis 
observed in SCD.
The association of proHDL with measures of hemolysis in univariate analysis was 
somewhat discordant. Although correlations were observed with lactate dehydrogenase, as 
well as total and indirect bilirubin, no significant associations were observed with 
hemoglobin or reticulocyte count. Furthermore, the observed association of proHDL with 
both lactate dehydrogenase and direct bilirubin in the final model of the multivariable 
analysis, combined with usual increases in the levels of lactate dehydrogenase and direct 
bilirubin in liver disease, suggest that proHDL may be associated with liver dysfunction. 
The liver plays a central role in lipoprotein metabolism and is responsible for both 
degradation and synthesis of lipoproteins (34). Inflammation and injury of the liver induces 
a variety of metabolic changes that can negatively impact lipoprotein metabolism. Thus 
during chronic states of inflammation and oxidative stress, such as those that are known to 
occur in SCD (35,36), the injured liver may be unable to metabolize HDL properly (37), 
which may explain the observed correlations between proHDL and both lactate 
dehydrogenase and direct bilirubin in our patient population.
The negative correlation between total cholesterol and sVCAM-1 in both the univariate and 
multivariable analyses suggests that hypocholesterolemia may contribute to endothelial cell 
injury in SCD. This finding was surprising, and is in contrast to the observation that basal 
VCAM-1 protein expression is higher in hyperlipidemic mice (ApoE [−/−]) than in wild-
type mice (38). In addition, both VCAM-1 mRNA and protein levels are further increased 
by high fat diet, with a correlation of VCAM-1 mRNA and protein levels to plasma 
cholesterol, LDL and HDL, but not to triglyceride levels. Induction of VCAM-1 by high fat 
diet in blood vessel walls may be dependent on inflammation, initiated by modified 
lipoprotein particles such as oxidized phospholipids and short-chain aldehydes, which in 
turn activate VCAM-1 transcription via activation of NF-κB (39). It is possible, however, 
that extremes of cholesterol levels (i.e. too high or too low) may be detrimental to health by 
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causing endothelial cell injury. An alternative explanation is that the increased 
erythropoiesis associated with SCD may contribute to both lower cholesterol levels and 
increased endothelial injury for, as yet, unknown reasons.
SCD is also described as a hypercoagulable state (40). We observed an association between 
proHDL and F1+2, TAT and D-dimer in univariate analyses, suggesting that proHDL may 
promote coagulation activation in SCD. However, proHDL was not independently 
associated with markers of coagulation activation. The absence of significant associations 
between proHDL and markers of coagulation activation in the final model of the 
multivariable analysis may be a result of the association of proHDL with lactate 
dehydrogenase, a biomarker that has been reported to be associated with markers of 
coagulation activation (41). Oxidized LDL has been reported to significantly enhance tissue 
factor expression induced by the inflammatory mediator, bacterial lipopolysaccharide (LPS), 
in a time- and dose-dependent manner (42). In another study, low concentrations of oxidized 
LDL has been shown to enhance tissue factor expression in human monocyte-derived 
macrophages, whereas higher concentrations attenuate tissue factor expression both at 
baseline as well as following LPS stimulation (43). As proHDL enhances the formation of 
biologically active oxidized phospholipids, increased levels of proHDL likely contributes to 
coagulation activation by increasing levels of oxidized LDL.
Total cholesterol and proHDL were associated with suspected PHT in univariate analyses. In 
addition, proHDL was significantly correlated with echocardiography-derived TRV. This 
suggests that proHDL may contribute to the pathophysiology of pulmonary vasculopathy in 
SCD. The absence of a significant association between proHDL and suspected PHT in the 
final model of the multivariable analysis may be related to the association of proHDL with 
lactate dehydrogenase, as multiple studies have shown associations of both TRV and 
echocardiography-defined PHT with lactate dehydrogenase in SCD (44,45).
Our study has several limitations. Right heart catheterizations were not obtained to confirm 
the presence of PHT. Extensive tests were not obtained to assess liver function in study 
subjects. As with all cross-sectional studies, this analysis demonstrates associations, but 
cannot prove causation.
In summary, our study confirms and extends the findings of hypocholesterolemia in SCD, 
with an association of lower cholesterol levels with increased sVCAM-1, a marker of 
endothelial injury. The lack of association of markers of hemolysis with lipid variables in 
the final model of the multivariable analysis suggests that hemolysis and increased 
erythropoiesis are unlikely to be the sole causes of hypocholesterolemia in SCD. The level 
of proHDL is not increased in SCD compared to healthy control subjects. Higher proHDL 
levels are associated with TRV, suspected PHT and markers of coagulation activation in 
univariate analyses. The association of proHDL with direct bilirubin and lactate 
dehydrogenase in the final model of the multivariable analysis suggests that proHDL may be 
a biomarker of liver dysfunction in SCD.
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Table 1
Demographic and Laboratory Characteristics of Study Subjects
Variable N Sickle Cell Disease Median (IQR) or 
N (%)
N Healthy Controls Median 
(IQR) or N (%)
p Value
Age 117 38(29, 47) 11 37(26,49) 0.5515
Gender (Male) 117 41 (35%) 11 5 (45%) 0.4914
Genotype (SS) 117 91 (78%) 11 0 (0%) <0.0001
Genotype (SC) 13 (11%) 0 (0%)
Genotype (Sβ0) 5 (4%) 0 (0%)
Genotype (Sβ+) 8 (7%) 0 (0%)
Genotype (AA) 0 (0%) 11 (100%)
Body mass index 116 25.6 (22.2, 29.8) 11 22.7 (22.0,23.1)
White Blood Cell (× 109/L) 117 9.2 (7.8, 11.4) 11 6.8 (4.4,9.3) 0.0104
Hemoglobin (g/dL) 117 8.8 (7.6, 10.1) 11 13.4 (12.2,13.9) <0.0001
Platelet Count (× 109/L) 117 410 (314, 498) 11 222 (201,291) <0.0001
Reticulocyte Count (%) 116 6.6 (4.5, 9.4) 11 1.7 (1.3,2.2) <0.0001
Hemoglobin F (%) 116 6.0 (3.2, 10.9) 11 0.5 (0.3, 2.0) <0.0001
Absolute Neutrophil Count (× 109/L) 117 4.8 (3.9, 6.2) 11 3.8 (2.1, 4.5) 0.0068
Absolute Monocyte Count (× 109/L) 117 0.5 (0.3, 0.7) 11 0.3 (0.2,0.4) 0.0026
Lactate Dehydrogenase (U/L) 115 866.0 (65.02, 1214.0) 11 481 (380,537) <0.0001
Total Bilirubin (mg/dL) 117 1.9 (1.0, 3.0) 11 0.5 (0.3,0.6) <0.0001
Direct Bilirubin (mg/dL) 115 0.1 (0.09, 0.1) 11 0.09 (0.09,0.1) 0.0193
Indirect Biliribin (mg/dL) 115 1.7 (0.9, 2.8) 11 0.36 (0.2,0.51) <0.0001
Creatinine (mg/dL) 117 0.7 (0.6, 1) 11 1.0 (0.7,1.1) 0.1589
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Table 2
Association of Lipid Variables with Clinical Complications in Patients with Sickle Cell Disease
Lipid Variable Clinical Variable N Yes (Median, IQR) N No (Median, IQR) p value
Total Cholesterol History of Stroke 14 99.6 [83.0, 108.5] 103 103.0 [86.5, 123.3] 0.54
Avascular necrosis 48 103.3 [90.9, 121.7] 69 99.8 [85.0, 122.5] 0.35
History of leg ulcer 31 93.6 [83.8, 109.5] 86 103.1 [90.9, 123.8] 0.084
Use of hydroxyurea 65 102.4 [86.5, 120.1] 51 102.5 [86.8, 122.8] 0.85
History of retinopathy 37 96.7 [85.5, 117.2] 80 103.1 [88.3, 123.9] 0.22
Pain crisis ≥ 3 in previous year 66 102.4 [83.9, 117.9] 51 103.3 [89.6, 130.2] 0.38
History of acute chest syndrome 101 102.5 [86.4, 123.3] 16 102.6 [92.3, 112.0] 0.96
History of priapism 18 86.3 [80.1, 108.5] 67 102.8 [86.5, 120.3] 0.063
Suspected pulmonary hypertension 33 95.9 [80.1, 109.5] 84 104.9 [90.2, 123.9] 0.011
HDL-Cholesterol History of stroke 14 48.5 [32.0, 70.8] 103 42.0 [34.4, 50.6] 0.32
Avascular necrosis 48 43.5 [32.0, 56.3] 69 42.0 [35.0, 50.9] 0.71
History of leg ulcer 31 42.6 [33.0, 53.8] 86 42.0 [35.3, 52.9] 0.65
Use of hydroxyurea 65 42.6 [32.4, 52.0] 51 42.0 [35.0, 55.4] 0.71
History of retinopathy 37 40.0 [34.4, 48.2] 80 44.1 [34.0, 55.1] 0.39
Pain crisis ≥ 3 in previous year 66 42.9 [32.4, 53.8] 51 42.0 [35.0, 52.9] 0.80
History of acute chest syndrome 101 42.6 [34.0, 52.9] 16 41.4 [37.0, 52.9] 0.78
History of priapism 18 38.0 [33.0, 45.7] 67 48.2 [37.4, 55.6] 0.015
Suspected pulmonary hypertension 33 41.2 [34.4, 55.0] 84 42.8 [34.0, 52.4] 0.97
Pro-inflammatory HDL-Cholesterol History of stroke 13 3.4 [2.6, 4.1] 100 3.1 [2.1, 4.2] 0.41
Avascular necrosis 46 3.2 [2.4, 4.5] 67 3.0 [2.1, 4.0] 0.47
History of leg ulcer 31 3.8 [2.1, 4.6] 82 2.9 [2.2, 3.7] 0.094
Use of hydroxyurea 65 2.9 [2.1, 4.1] 47 3.3 [2.3, 4.3] 0.29
History of retinopathy 35 3.0 [2.2, 4.0] 78 3.2 [2.1, 4.3] 0.60
Pain crisis ≥ 3 in previous year 66 3.2 [2.2, 4.3] 47 3.1 [2.1, 4.0] 0.98
History of acute chest syndrome 99 3.2 [2.1, 4.2] 14 3.0 [2.5, 4.0] 0.95
History of priapism 18 2.7 [2.0, 4.0] 63 3.7 [2.7, 4.6] 0.035
Suspected pulmonary hypertension 30 3.6 [2.7, 5.0] 83 2.9 [2.0, 4.0] 0.0099
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Table 3
Correlation of Lipid Variables with Laboratory Measures of Hemolysis and Inflammation in Patients with 
Sickle Cell Disease
Lipid Variable Laboratory Variable Number of Patients r value (95%) Confidence Interval p value
Total Cholesterol White blood count 117 −0.031 −0.212 – 0.151 0.74
Absolute neutrophil count 117 0.106 −0.077 – 0.283 0.25
Absolute monocyte count 117 0.022 −0.160 – 0.203 0.81
Hemoglobin 117 0.159 −0.023 – 0.331 0.085
Platelet count 117 −0.014 −0.195 – 0.168 0.88
Reticulocyte count 116 −0.096 −0.273 – 0.088 0.31
Hemoglobin F 116 0.186 0.004 – 0.356 0.045
Lactate dehydrogenase 115 −0.20 −0.370 - −0.018 0.031
Total bilirubin 117 −0.215 −0.382 - −0.035 0.019
Direct bilirubin 115 0.020 −0.164 – 0.202 0.84
Indirect bilirubin 115 −0.197 −0.367 - −0.015 0.034
NT-proBNP 114 −0.048 −0.230 – 0.137 0.61
Soluble VCAM-1 117 −0.336 −0.488 - −0.164 0.0002
Thrombin-antithrombin complexes 109 0.006 −0.183 – 0.193 0.95
D-dimer 105 −0.082 −0.269 – 0.111 0.40
Prothrombin 1+2 69 −0.097 −0.326 – 0.143 0.43
HDL-Cholesterol White blood count 117 −0.020 −0.200 – 0.162 0.8333
Absolute neutrophil count 117 −0.126 −0.300 – 0.057 0.1758
Absolute monocyte count 117 −0.068 −0.247 – 0.115 0.4646
Hemoglobin 117 0.002 −0.180 – 0.183 0.9865
Platelet count 117 −0.206 −0.374 - −0.026 0.0247
Reticulocyte count 116 0.027 −0.156 – 0.208 0.7748
Hemoglobin F 116 −0.088 −0.266 – 0.095 0.3438
Lactate dehydrogenase 115 0.055 −0.130 – 0.235 0.56
Total bilirubin 117 0.103 −0.080 – 0.280 0.27
Direct bilirubin 115 0.389 0.220 – 0.533 <0.0001
Indirect bilirubin 115 0.086 −0.099 – 0.265 0.36
NT-proBNP 114 −0.007 −.0.177 – 0.191 0.94
Soluble VCAM-1 117 −0.012 −0.0193 – 0.170 0.90
Thrombin-antithrombin complexes 109 0.119 −0.072 – 0.299 0.22
D-dimer 105 0.154 −0.039 – 0.336 0.12
Prothrombin 1+2 69 0.171 −0.068 – 0.392 0.16
Pro-inflammatory HDL-Cholesterol White blood count 113 −0.037 −0.220 – 0.148 0.69
Absolute neutrophil count 113 −0.094 −0.274 – 0.092 0.32
Absolute monocyte count 113 −0.001 −0.186 – 0.184 0.99
Hemoglobin 113 −0.140 −0.317 – 0.046 0.14
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Lipid Variable Laboratory Variable Number of Patients r value (95%) Confidence Interval p value
Platelet count 113 −0.108 −0.287 – 0.079 0.26
Reticulocyte count 112 0.122 −0.065 – 0.301 0.20
Hemoglobin F 112 −0.147 −0.324 – 0.039 0.12
Lactate dehydrogenase 111 0.310 0.131 – 0.469 0.0008
Total bilirubin 113 0.233 0.050 – 0.400 0.013
Direct bilirubin 111 0.481 0.322 – 0.611 <0.0001
Indirect bilirubin 111 0.208 0.022 – 0.380 0.028
NT-proBNP 110 0.132 −0.057 – 0.311 0.17
Soluble VCAM-1 113 0.118 −0.068 – 0.296 0.21
Thrombin-antithrombin complexes 105 0.221 0.030 – 0.395 0.023
D-dimer 101 0.274 0.082 – 0.445 0.0053
Prothrombin 1+2 65 0.332 0.096 – 0.533 0.0062
NT-proBNP – N-terminal pro-brain natriuretic peptide
Soluble VCAM-1 – Soluble vascular cell adhesion molecule-1
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Table 4
Multivariable Analysis
Dependent Variable Covariate Number of patients Estimate Standard Error 95% Confidence Interval p value
Total Cholesterol Intercept 117 122.05 5.78 110.71, 133.39 <0.0001
Soluble VCAM-1 −0.015 0.005 −0.026, −0.005 0.003
HDL Cholesterol Intercept 109 43.26 1.52 40.28, 46.23 <0.0001
Thrombin anti-thrombin complex 0.068 0.033 0.0035, 0.13 0.039
Pro-inflammatory HDL Cholesterol Intercept 110 1.91 0.31 1.29, 2.52 <0.0001
Direct bilirubin 1.4 0.71 0.02, 2.78 0.047
Lactate dehydrogenase 0.0011 0.00029 0.0005, 0.0016 0.00024
Soluble VCAM-1 – Soluble vascular cell adhesion molecule – 1
HDL cholesterol – High density lipoprotein cholesterol
LDL cholesterol – High density lipoprotein cholesterol
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